Results 1 to 10 of about 1,350,423 (267)

The blood proteome of imminent lung cancer diagnosis

Nature Communications, 2023
Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within ...
The Lung Cancer Cohort Consortium (LC3)
doaj   +1 more source

Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching’s Study

Frontiers in Oncology, 2021
BackgroundTo investigate the differences in survival between lobectomy and sub-lobar resection for elderly stage I non-small-cell lung cancer (NSCLC) patients using the Surveillance, Epidemiology, and End Results (SEER) registry.MethodThe data of stage ...
Bo Zhang, Renwang Liu, Dian Ren, Xiongfei Li, Yanye Wang, Huandong Huo, Shuai Zhu, Jun Chen, Jun Chen, Zuoqing Song, Zuoqing Song, Song Xu, Song Xu   +12 more
doaj   +1 more source

Clinical significance of preoperative neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio in the prognosis of resected early‐stage patients with non‐small cell lung cancer: A meta‐analysis

Cancer Medicine, 2023
Background Poor prognosis is linked to peripheral blood levels of preoperative platelet‐lymphocyte ratio (PLR) and neutrophil‐lymphocyte ratio (NLR) in many advanced cancers. Nevertheless, whether the correlation exists in resected early‐stage cases with
Weibo Cao, Haochuan Yu, Shuai Zhu, Xi Lei, Tong Li, Fan Ren, Ning Zhou, Quanying Tang, Lingling Zu, Song Xu   +9 more
doaj   +1 more source

Systematic pan-cancer analysis showed that RAD51AP1 was associated with immune microenvironment, tumor stemness, and prognosis

Frontiers in Genetics, 2022
Although RAD51 associated protein 1 (RAD51AP1) is crucial in genome stability maintenance, it also promotes cancer development with an unclear mechanism.
Renwang Liu, Renwang Liu, Guangsheng Zhu, Guangsheng Zhu, Mingbiao Li, Peijun Cao, Peijun Cao, Xuanguang Li, Xuanguang Li, Xiuwen Zhang, Xiuwen Zhang, Hua Huang, Hua Huang, Zuoqing Song, Zuoqing Song, Jun Chen, Jun Chen   +16 more
doaj   +1 more source

Lobectomy versus sublobar resection for stage I (T1‐T2aN0M0) small cell lung cancer: A SEER population‐based propensity score matching analysis

Cancer Medicine, 2023
Objective This study evaluated whether sublobar resection (sub‐L) is non‐inferior to lobectomy (L) for stage I (T1‐T2aN0M0) small cell lung cancer (SCLC) regarding long‐term overall survival (OS).
Ning Zhou, Lingqi Yang, Bo Zhang, Shuai Zhu, Huandong Huo, Jinling He, Lingling Zu, Zuoqing Song, Song Xu   +8 more
doaj   +1 more source

To Explore the Effects of Acupuncture and Medical Treatment at Different Times on the Gastrointestinal Reaction and White Blood Cell Count of Patients with Lung Cancer Chemotherapy

Applied Bionics and Biomechanics, 2022
Objective. To explore and analyze the effects of acupuncture and medical treatment at different times on the gastrointestinal reaction and leukocyte count of patients with lung cancer undergoing chemotherapy. Methods.
Qingchun Zhao, Hui Du, Jinghao Liu, Yu Hua, Xiaoyu Niu, Jun Chen   +5 more
doaj   +1 more source

MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma: 
A Case Report and Literature Review

Chinese Journal of Lung Cancer, 2021
Small cell lung cancer (SCLC) is the most malignant lung cancer with the highest mortality. At present, the first-line standard treatment is still based on Etoposide and Platinum chemotherapy.
Zihan QU, Jiewei LIU, Feng LUO, Lu LI, Lingling ZHU, Qinghua ZHOU   +5 more
doaj   +1 more source

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

Frontiers in Oncology, 2021
The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis.
Dan Pu, Liyuan Yin, Lin Huang, Changlong Qin, Yuwen Zhou, Qiang Wu, Yan Li, Qinghua Zhou, Lu Li   +8 more
doaj   +1 more source

Symptom trajectories during chemotherapy in patients with non‐small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy

Thoracic Cancer, 2021
Background Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC.
Jinghao Liu, Xingyu Liu, Ming Dong, Honglin Zhao, Mei Li, Hongbing Zhang, Huihui Ji, Yi Shi, Yajie Cui, Di Wu, Gang Chen, Jun Chen   +11 more
doaj   +1 more source

EGFR-TKI ADR Management Chinese Expert Consensus

Chinese Journal of Lung Cancer, 2019
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj   +1 more source